The scientist, Dr. Fiona Havers, told colleagues at the Centers for Disease Control and Prevention on Monday that she no ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- ...

Fiona Havers, who oversees CDC respiratory virus data, told colleagues she no longer had confidence the data would be used ...

A Centers for Disease Control and Prevention official who led the agency's network to study hospitalization trends from infectious diseases like COVID-19 has resigned in protest following Health and ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...